Prognostic Indicators Involved In NK T Cell Lymphoma

The term NK T cell lymphoma refers to one of two subtypes of lymphoma that affect the NK (Natural Killer) cells of the immune system. They are:

This subtype of lymphoma most often occurs in the nose or nasopharynx, and presents first as a nasal obstruction and/or nasal discharge.

Call

Prognostic Indicators

Certain specific factors have been found to serve as fairly reliable prognostic indicators of extranodal NK T cell lymphoma. They are:

  • Stage at diagnosis (the lower the better)
  • Age (under age 60 = better prognosis)
  • Absence or presence of B symptoms (the absence of B symptoms suggests a better prognosis)
  • Performance status (i.e. how affected is the patient by the disease? The less affected, the better the prognosis).

Ultimately, NK T cell lymphoma has very poor survival rates and general prognoses. For instance, overall survival of patients with extranodal NK T cell lymphoma is 30-40%, meaning that 3 or 4 of every ten patients with this disease is expected to be alive five years from diagnosis. The news is much worse for aggressive NK cell leukemia—most patients do not survive more than a few months after initial symptoms appear.

Treating NK T Cell Lymphoma

There is currently no clear consensus in the cancer community regarding the best and most effective first-line treatment for NK T cell lymphoma. In some cases, radiotherapy is the preferred treatment, since NK T cell lymphoma does not traditionally respond well to conventional chemotherapeutic regimens, but to this end they are the only modes of treatment that have been explored to any reasonable degree. Depending on the disease and the patient, treatment may include chemotherapy regimens such as CHOP, DA-EPOCH, or SMILE, followed by radiation.

Sources

  • Wong KF. NK cell neoplasias. Atlas Genet Cytogenet Oncol Haematol.
  • National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphomas, V.I.

Photo: Pexels

Call

More Articles

More Articles

This entry looks at Non Hodgkin's Lymphoma in the lungs, clinically known as pulmonary lymphoma, one of the subtypes of lymphoma. 'Lymphoma' is an...

In order to prevent developing any subtype of lymphoma, it would be helpful to know the causes of lymphoma. Unfortunately, in virtually every case...

BEAM chemotherapy is an acronym representing a small family of combination chemotherapy regimens that are used chiefly as salvage regimens in the...

There are two types of cancer: benign and malignant. Benign cancers are the kind that don't spread and don't threaten one's life. Malignant...

The Erythrocyte Sedimentation Rate (ESR - sometimes called sed rate or sedimentation rate) is a nonspecific screening test for various...

Blood counts can be used to identify disease and monitor patient health during cancer treatments. Though these tests cannot diagnose lymphoma on...

MALT lymphoma is a rare B-cell non-Hodgkin's lymphoma that typically runs an indolent or slow-growing clinical...

Mantle cell lymphoma (MCL) is just one of 50-60 known B-cell subtypes of...

After some of the dust has settled, the thoughts of many new lymphoma patients turn to diet and nutrition. They want to know if, in the past,...

According to a study by Japanese researchers, the SMILE combination chemotherapy protocol is effective against extranodal natural killer/T-cell...

In a perfect world, every case of cancer would respond to, and be cured by first-line therapy. Unfortunately, it is not often the case. This is...

Patients treated with maintenance rituximab had three times longer progression-free survival. This is a summary of an article published in the...

Prednisone is a glucocorticosteroid (a steroid) used in the treatment of many types of cancers. It functions as an anti-inflammatory medicine that...

In 1964, researchers at the National Cancer Institute developed the first combination chemotherapy that cured a...

Since so many chemotherapy agents can affect a patient’s sex drive and fertility, thinking about these issues prior...